Sonja Vliek, Florentine S Hilbers, Erik van Werkhoven, Ingrid Mandjes, Rob Kessels, Sieta Kleiterp, Esther H Lips, Lennart Mulder, Mutamba T Kayembe, Claudette E Loo, Nicola S Russell, Marie-Jeanne T F D Vrancken Peeters, Marjo J Holtkamp, Margaret Schot, Joke W Baars, Aafke H Honkoop, Annelie J E Vulink, Alex L T Imholz, Suzan Vrijaldenhoven, Franchette W P J van den Berkmortel, Jetske M Meerum Terwogt, Jolanda G Schrama, Philomeen Kuijer, Judith R Kroep, Annemieke van der Padt-Pruijsten, Jelle Wesseling, Gabe S Sonke, Kenneth G A Gilhuijs, Agnes Jager, Petra Nederlof, Sabine C Linn
Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients with BRCA-altered tumors who had received three initial courses of dose-dense doxorubicin and cyclophosphamide (ddAC), were randomized between a fourth ddAC course followed by high-dose carboplatin-thiotepa-cyclophosphamide or conventional chemotherapy (initially ddAC only or ddAC-capecitabine/decetaxel [CD] depending on MRI response, after amendment ddAC-carboplatin/paclitaxel [CP] for everyone)...
September 9, 2023: NPJ Breast Cancer